NCT05642546 - First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 12, 2020

Primary Completion Date

June 15, 2022

Study Completion Date

June 15, 2022

Conditions

Healthy

Interventions

DRUG

NM8074

Novel, recombinant, humanized monoclonal antibody that selectively binds to human Factor Bb with high affinity and blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases

DRUG

Placebo

Saline Placebo

Trial Locations (1)

75247

Covance Clinical Unit, Dallas